Abstract
Purpose: TG-C (3:1 mixture of non-irradiated allogeneic human chondrocytes and irradiated allogeneic human GP2-293 cells transduced with a retroviral vector that encodes transforming growth factor-beta 1 [TGF-β1]) is a cell-mediated gene therapy that is under development for the treatment of osteoarthritis (OA) of the knee. The safety and efficacy of a single intra-articular injection of TG-C into the knee joint have been evaluated in a Phase 1, multicenter, single-blind, randomized, placebo-controlled, dose-escalation trial and in a Phase 2, multicenter, double-blind, randomized, placebo-controlled, fixed-dose trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
